Clinical trials raise a variety of benefit-cost and cost-effectiveness considerations. To date, these considerations have received minimal attention from persons performing trials. Analysis of the benefit-cost aspects of a trial should shed additional light on, or add a new dimension to, the...

There are ongoing debates regarding the nature and scope of intellectual property protection, if any, which clinical trial data should receive in terms of Article 39 of the TRIPS Agreement.These debates however occur in the international and bilateral contexts thus excluding key stakeholders in...

In this paper we document a process of price convergence in the European market for pharmaceutical products and relate it to access to innovative medicines in individual countries. The EU is a peculiar case study, where free circulation of goods coexists with pricing policies designed and...

Background Although medical oncologists can have an important role in controlling the cost of cancer treatment, there is little information about their attitudes toward the cost of cancer treatment and the impact of cost on their treatment recommendations, especially in low- and middle-income...